Ginkgo Bioworks Holdings Price to Free Cash Flow Ratio 2020-2022 | DNA

Historical price to free cash flow ratio values for Ginkgo Bioworks Holdings (DNA) since 2020. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Ginkgo Bioworks Holdings Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-02-03 2.06 0.00
2022-09-30 3.12 $-0.23 0.00
2022-06-30 2.38 $-0.21 0.00
2022-03-31 4.03 $-0.24 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.996B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00